A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Phase 1
542
about 7 years
18+
30 sites in AL, AZ, CA +14
About this study
This trial is testing different treatments, including drugs and immunotherapy, to see if they are safe and effective for people with advanced colorectal cancer whose tumors have specific biomarkers. Participants will be assigned to treatment arms based on their biomarker results.
Based on ClinicalTrials.gov records.
What participants do
- 1.FoundationOne®Liquid CDx
- 2.Take Atezolizumab
- 3.Take Bevacizumab
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
atezolizumab, bevacizumab, cetuximab, Antineoplastic Agent [TC] (Phosphoinositide 3-Kinase alpha Inhibitors), monoclonal antibody
injection (Injection), infusion, oral (Oral Tablet)
Primary: Objective Response Rate
Secondary: Disease Control Rate, Duration of Response, Percentage of Participants with Adverse Events (AEs)
Oncology